ProCE Banner Activity

ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor as First-line Therapy for Chronic Myeloid Leukemia in Chronic Phase

Conference Coverage
Slideset

Updated data from the phase III ASC4FIRST trial of asciminib vs investigator-selected TKI demonstrated superior efficacy and manageable safety and tolerability profile with asciminib when used as first-line therapy for patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Released: December 11, 2024

Expiration: December 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation